These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81. Connolly D; Hutton R; Keane PF Eur Urol; 2011 Mar; 59(3):e9; author reply e10-1. PubMed ID: 21145647 [No Abstract] [Full Text] [Related]
4. [Dutasteride provides chemoprevention]. Werner F Aktuelle Urol; 2006 Sep; 37(5 Suppl):18. PubMed ID: 23646395 [No Abstract] [Full Text] [Related]
5. Current prospects for the chemoprevention of prostatic cancer. Kirk D BJU Int; 2010 Dec; 106(11):1826-7. PubMed ID: 21078043 [No Abstract] [Full Text] [Related]
7. Prostate cancer: A closer look at the initial results from the REDUCE trial. Gann PH Nat Rev Urol; 2010 Oct; 7(10):535-7. PubMed ID: 20930862 [No Abstract] [Full Text] [Related]
8. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. Theoret MR; Ning YM; Zhang JJ; Justice R; Keegan P; Pazdur R N Engl J Med; 2011 Jul; 365(2):97-9. PubMed ID: 21675880 [No Abstract] [Full Text] [Related]
9. Dutasteride: novel milestones in prostate cancer chemoprevention. Rove KO; Crawford ED Drugs Today (Barc); 2011 Feb; 47(2):135-44. PubMed ID: 21431101 [TBL] [Abstract][Full Text] [Related]
10. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen. Svatek RS; Lotan Y Cancer Prev Res (Phila); 2011 Feb; 4(2):277-83. PubMed ID: 21163937 [TBL] [Abstract][Full Text] [Related]
11. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Musquera M; Fleshner NE; Finelli A; Zlotta AR Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452 [TBL] [Abstract][Full Text] [Related]
12. Re: Fritz H. Schröder, Karl-Heinz Kurth, Sophie D. Fossa, et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009;55:14-22. Drewa T Eur Urol; 2009 May; 55(5):e82-3. PubMed ID: 18950934 [No Abstract] [Full Text] [Related]
13. Dutasteride (Avodart) for prevention of prostate cancer. Med Lett Drugs Ther; 2010 Apr; 52(1336):29. PubMed ID: 20407415 [No Abstract] [Full Text] [Related]
14. Reply: To PMID 25623680. Vickers AJ Urology; 2015 Feb; 85(2):342. PubMed ID: 25623682 [No Abstract] [Full Text] [Related]